PAQ Therapeutics Unveils First Clinical Data for KRAS G12D Degrader PT0253 at EORTC-NCI-AACR 2026 Symposium#USA#Burlington#PAQ_Therapeutics#PT0253#KRAS_G12D
PAQ Therapeutics Unveils First Clinical Data for KRAS G12D Degrader PT0253 at EORTC-NCI-AACR 2026 Symposium
The upcoming EORTC-NCI-AACR Symposium will showcase PAQ Therapeutics’ promising data on their KRAS G12D degrader, PT0253, addressing unmet cancer needs.
third-news.com
November 3, 2026 at 12:27 PM
PAQ Therapeutics Unveils First Clinical Data for KRAS G12D Degrader PT0253 at EORTC-NCI-AACR 2026 Symposium#USA#Burlington#PAQ_Therapeutics#PT0253#KRAS_G12D
PAQ Therapeutics Secures $39 Million Funding and Launches Innovative Phase 1 Trial for KRAS-Driven Cancers#USA#Burlington#PAQ_Therapeutics#KRAS_Degraders#PT0253
PAQ Therapeutics Secures $39 Million Funding and Launches Innovative Phase 1 Trial for KRAS-Driven Cancers
PAQ Therapeutics has raised $39 million to advance its Phase 1 trial targeting KRAS-driven cancers, showcasing a groundbreaking approach with its lead compound PT0253.
third-news.com
May 7, 2025 at 11:24 AM
PAQ Therapeutics Secures $39 Million Funding and Launches Innovative Phase 1 Trial for KRAS-Driven Cancers#USA#Burlington#PAQ_Therapeutics#KRAS_Degraders#PT0253